NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
Hookipa Biotech GmbH
Skin Analytics Limited
Nantes University Hospital
Fudan University
AHS Cancer Control Alberta
Merck KGaA, Darmstadt, Germany
Icahn School of Medicine at Mount Sinai